drugset / Trial / NCT06839872
A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To assess the efficacy and safety of pirtobrutinib in participants with CLL/SLL who have progressed on first-line treatment with acalabrutinib.
Timeline
- Start
- 2025-06-30
- Primary completion
- 2028-07-28
- Completion
- 2030-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | — | Oral |
| Subject | Pirtobrutinib | Other / unclassified | — | Oral |